Literature DB >> 22270083

Lower serum IL-10 is an independent predictor of IBS among volunteers in Mexico.

Max Schmulson1, Daniela Pulido-London, Oscar Rodriguez, Norma Morales-Rochlin, Rosalinda Martinez-García, Ma Concepción Gutierrez-Ruiz, Juan Carlos López-Alvarenga, Guillermo Robles-Díaz, Gabriela Gutiérrez-Reyes.   

Abstract

OBJECTIVES: Studies suggest that altered immune activation, manifested by an imbalance in anti- and pro-inflammatory cytokine levels, exists in a subgroup of irritable bowel syndrome (IBS) patients. However, similar studies have not been conducted in Latin populations. The objective of this study was to measure serum levels of interleukin (IL)-10 and tumor necrosis factor (TNF)-α in subjects fulfilling symptom criteria for IBS and controls.
METHODS: Volunteers (n=178) from a university population in Mexico City, participated in the study. Of the sample, 34.8% met Rome II criteria for IBS and 65.2% were designated as controls. Serum cytokines were measured by enzyme-linked immunoabsorbent assay. Analysis of covariance models were used to test main effects between gender, IBS symptoms, and bowel habit subtype to explain the cytokine serum levels. Statistical models were tested using body mass index as a covariate.
RESULTS: IL-10 levels were significantly lower in IBS vs. controls (mean (95% confidence interval): 15.6 (14.8, 16.3) vs. 18.6 (17.9, 19.4) pg/ml, P<0.001), while TNF-α levels were higher in IBS (20.9 (19.1, 23.0) vs. 17.9 (16.7, 19.3) pg/ml, P=0.010). IBS and female gender were independent predictors for IL-10 (P<0.05). In contrast, female gender was an independent predictor for TNF-α. In addition, women with IBS-D had the lowest IL-10 (P<0.001) and highest TNF-α (P=0.021) vs. other subtypes.
CONCLUSIONS: The lower serum IL-10 in our subjects fulfilling IBS Rome II symptom criteria suggests an altered immune regulation. Further studies are needed to elucidate if a lower serum IL-10 may be useful as a biomarker for IBS in the Mexican population, especially for women with IBS-D.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22270083     DOI: 10.1038/ajg.2011.484

Source DB:  PubMed          Journal:  Am J Gastroenterol        ISSN: 0002-9270            Impact factor:   10.864


  17 in total

Review 1.  What does irritable bowel syndrome share with non-alcoholic fatty liver disease?

Authors:  Antonella Scalera; Matteo Nicola Dario Di Minno; Giovanni Tarantino
Journal:  World J Gastroenterol       Date:  2013-09-07       Impact factor: 5.742

2.  Global Cytokine Profiles and Association With Clinical Characteristics in Patients With Irritable Bowel Syndrome.

Authors:  Sean M P Bennet; Annikka Polster; Hans Törnblom; Stefan Isaksson; Sandrine Capronnier; Aurore Tessier; Boris Le Nevé; Magnus Simrén; Lena Öhman
Journal:  Am J Gastroenterol       Date:  2016-06-07       Impact factor: 10.864

Review 3.  Association of interleukin-10 polymorphisms with risk of irritable bowel syndrome: a meta-analysis.

Authors:  Shan-Yu Qin; Hai-Xing Jiang; Dong-Hong Lu; You Zhou
Journal:  World J Gastroenterol       Date:  2013-12-28       Impact factor: 5.742

Review 4.  Overlap between functional GI disorders and other functional syndromes: what are the underlying mechanisms?

Authors:  S E Kim; L Chang
Journal:  Neurogastroenterol Motil       Date:  2012-08-02       Impact factor: 3.598

Review 5.  Irritable bowel syndrome: a gut microbiota-related disorder?

Authors:  Yogesh Bhattarai; David A Muniz Pedrogo; Purna C Kashyap
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2016-11-23       Impact factor: 4.052

Review 6.  Natural polyphenols for the prevention of irritable bowel syndrome: molecular mechanisms and targets; a comprehensive review.

Authors:  Nazanin Momeni Roudsari; Naser-Aldin Lashgari; Saeideh Momtaz; Mohammad Hosein Farzaei; André M Marques; Amir Hossein Abdolghaffari
Journal:  Daru       Date:  2019-07-04       Impact factor: 3.117

7.  Associations among gut permeability, inflammatory markers, and symptoms in patients with irritable bowel syndrome.

Authors:  Robert J Shulman; Monica E Jarrett; Kevin C Cain; Elizabeth K Broussard; Margaret M Heitkemper
Journal:  J Gastroenterol       Date:  2014-01-17       Impact factor: 7.527

8.  Cytokine Levels and Symptoms Among Women with Irritable Bowel Syndrome: Considering the Role of Hormonal Contraceptive Use.

Authors:  Kendra J Kamp; Claire Han; Robert J Shulman; Kevin C Cain; Pamela Barney; Mark R Opp; Lin Chang; Robert L Burr; Margaret M Heitkemper
Journal:  Biol Res Nurs       Date:  2020-07-17       Impact factor: 2.522

9.  Effect of Triticum turgidum subsp. turanicum wheat on irritable bowel syndrome: a double-blinded randomised dietary intervention trial.

Authors:  Francesco Sofi; Anne Whittaker; Anna Maria Gori; Francesca Cesari; Elisabetta Surrenti; Rosanna Abbate; Gian Franco Gensini; Stefano Benedettelli; Alessandro Casini
Journal:  Br J Nutr       Date:  2014-02-13       Impact factor: 3.718

10.  Chemotactic chemokines are important in the pathogenesis of irritable bowel syndrome.

Authors:  Charles Darkoh; Latoya Comer; Getie Zewdie; Stephen Harold; Ned Snyder; Herbert L Dupont
Journal:  PLoS One       Date:  2014-03-25       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.